Shamburg News · 8-K filed Oct 29, 2026, 7:03 AM EDT
Altimmune Draws $10.0 Million Tranche Three Under Hercules Loan Agreement
ALT · Altimmune, Inc.
- Financing
- Material agreement
- Materiality: medium
On October 27, 2026, Altimmune, Inc. drew $10.0 million in aggregate principal (Tranche Three) from its $125.0 million Loan and Security Agreement with Hercules Capital, Inc. and other lenders, following achievement of specified clinical and financial milestones. The amortization date and interest-only period were extended to June 1, 2028, and the company must maintain Qualified Cash of at least 60% of outstanding Term Loan Advances. A Tranche Facility Charge of 1.0% was netted from the funding.
Source: SEC EDGAR, Form 8-K, Item 2.03, accession 0001326190-26-000060.
Written from the filing by Shamburg Markets. Figures are as reported by the company.